{"filing":{"accession_number":"0001437749-26-023199","cik":"0000811641","ticker":"ICCC","company_name":"IMMUCELL CORP /DE/","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"iccc20260708_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926023199/iccc20260708_8k.htm"},"events":[{"id":16831,"run_id":15058,"accession_number":"0001437749-26-023199","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ImmuCell issued a press release on July 9, 2026 announcing preliminary, unaudited Q2 2026 sales results showing an 11.5% increase in product sales compared to Q2 2025 ($7.2M vs. $6.4M), with strong domestic growth of 27.7%. The full press release is attached as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02. This is a material earnings announcement that would affect a reasonable investor's assessment of the company's financial performance.","company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15047,"accession_number":"0001437749-26-023199","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ImmuCell issued a press release on July 9, 2026 announcing preliminary, unaudited Q2 2026 sales results showing an 11.5% increase in product sales compared to Q2 2025 ($7.2M vs. $6.4M), with strong domestic growth of 27.7%. The full press release is attached as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02. This is a material earnings announcement that would affect a reasonable investor's assessment of the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:37:57.560569+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15047,"accession_number":"0001437749-26-023199","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ImmuCell issued a press release on July 9, 2026 announcing preliminary, unaudited Q2 2026 sales results showing an 11.5% increase in product sales compared to Q2 2025 ($7.2M vs. $6.4M), with strong domestic growth of 27.7%. The full press release is attached as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02. This is a material earnings announcement that would affect a reasonable investor's assessment of the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:37:57.560569+00:00","company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","filing_date":"2026-07-09"}]}